ADCT 211
Alternative Names: ADCT-211Latest Information Update: 22 Jun 2023
Price :
$50 *
At a glance
- Originator ADC Therapeutics
- Class Antibodies; Antineoplastics; Benzodiazepines; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Jun 2023 ADC Therapeutics plans a clinical trial in Cancer
- 20 Jun 2023 ADCT 211 is available for licensing as of 20 Jun 2023. https://www.adctherapeutics.com/our-company/#partnering (ADC Therapeutics, June 2023).
- 14 Apr 2023 Preclinical trials in Solid tumours in Switzerland (Parenteral) prior to April 2023